The Biased GLP-1 Signal: Ecnoglutide’s 35% Edge Over Semaglutide Is the Opening Shot in Obesity’s Next Competitive War
Sciwind's ecnoglutide beat semaglutide by 35% on weight loss in a head-to-head trial—and it signals a coming wave of...
Obesity Drug Market
The Triple Threat: Incretin Multi-Agonists Are About to Redraw the $77B Obesity Map
Nature Reviews flags incretin multi-agonist reversal of obesity and diabetes — Lilly's retatrutide Phase 3 data signals the GLP-1...
Novo Nordisk’s 20.7% Weight Loss Number Changes the GLP-1 Rulebook
Novo Nordisk's Wegovy 7.2 mg CHMP approval delivers 20.7% mean weight loss — rewriting competitive benchmarks for Eli Lilly's...